Levodopa in Parkinsonism: potentiation of central effects with a peripheral inhibitor.
D000284:Administration, Oral; D000328:Adult; D001711:Biotransformation / Q000187:drug effects; D001921:Brain / Q000187:drug effects*; D002249:Carbon Monoxide Poisoning / Q000188:drug therapy; D002547:Cerebral Palsy / Q000188:drug therapy; D002648:Child; D002986:Clinical Trials as Topic; D004295:Dihydroxyphenylalanine / Q000008:administration & dosage / Q000009:adverse effects / Q000378:metabolism / Q000494:pharmacology / Q000627:therapeutic use*; D004298:Dopamine / Q000378:metabolism / Q000652:urine; D004357:Drug Synergism; D005260:Female; D006801:Humans; D006834:Hydrazines / Q000627:therapeutic use; D008297:Male; D008750:Methyldopa / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use; D009460:Neurologic Examination; D009468:Neuromuscular Diseases / Q000188:drug therapy; D010300:Parkinson Disease / Q000188:drug therapy*; D010648:Phenylacetates / Q000652:urine; D011736:Pyridoxine / Q000008:administration & dosage / Q000494:pharmacology; D013997:Time Factors
D006834:Hydrazines; D010648:Phenylacetates; D008750:Methyldopa; D004295:Dihydroxyphenylalanine; D011736:Pyridoxine; D004298:Dopamine